4 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Pancreatic Diseases"
Show Display Options
Rank Status Study
1 Recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer (BRCA1, BRCA2);   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Prostate Cancer;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
2 Recruiting Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
Condition: Stage IV Pancreatic Cancer
Interventions: Drug: nab-paclitaxel;   Drug: Cisplatin;   Drug: gemcitabine
3 Recruiting A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Condition: Resectable Pancreatic Cancer
Intervention: Drug: LDE-225
4 Recruiting Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
Condition: Cystic Fibrosis
Interventions: Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder

Indicates status has not been verified in more than two years